Immediate Impact
2 from Science/Nature 69 standout
Citing Papers
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
2025 Standout
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment
2025 Standout
Works of Débora S. Bruno being referenced
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.
2023
ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Débora S. Bruno | 197 | 118 | 80 | 43 | 322 | |
| Nancy Nixon | 226 | 65 | 40 | 25 | 330 | |
| Jin Piao | 137 | 51 | 50 | 49 | 341 | |
| Vishal Navani | 192 | 154 | 45 | 38 | 302 | |
| Deirdre Kelly | 156 | 79 | 100 | 28 | 333 | |
| Jared D. Acoba | 163 | 47 | 33 | 38 | 319 | |
| Tyler Johnson | 246 | 56 | 122 | 29 | 368 | |
| Shivanshu Awasthi | 137 | 224 | 90 | 27 | 335 | |
| Alejandro Ruíz-Patiño | 135 | 123 | 83 | 38 | 349 | |
| Mitchell S. von Itzstein | 205 | 96 | 24 | 32 | 317 | |
| Abhenil Mittal | 95 | 68 | 58 | 53 | 302 |
All Works
Loading papers...